ADENOSCAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Adenoscan, and what generic alternatives are available?
Adenoscan is a drug marketed by Astellas and is included in one NDA.
The generic ingredient in ADENOSCAN is adenosine. There are twenty-six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the adenosine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Adenoscan
A generic version of ADENOSCAN was approved as adenosine by HIKMA on June 16th, 2004.
Summary for ADENOSCAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 161 |
| Clinical Trials: | 10 |
| Patent Applications: | 2,138 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ADENOSCAN at DailyMed |
Recent Clinical Trials for ADENOSCAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| NYU Langone Health | N/A |
| University of Utah | Early Phase 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | Early Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for ADENOSCAN
US Patents and Regulatory Information for ADENOSCAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | ADENOSCAN | adenosine | SOLUTION;INTRAVENOUS | 020059-001 | May 18, 1995 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Astellas | ADENOSCAN | adenosine | SOLUTION;INTRAVENOUS | 020059-002 | May 18, 1995 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ADENOSCAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Astellas | ADENOSCAN | adenosine | SOLUTION;INTRAVENOUS | 020059-002 | May 18, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Astellas | ADENOSCAN | adenosine | SOLUTION;INTRAVENOUS | 020059-001 | May 18, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Astellas | ADENOSCAN | adenosine | SOLUTION;INTRAVENOUS | 020059-001 | May 18, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ADENOSCAN
See the table below for patents covering ADENOSCAN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1301652 | ADMINISTRATION INTRAVEINEUSE PROGRESSIVE DE L'ADENOSINE A DES SUJETS HUMAINS (CONTINUOUS INTRAVENOUS INFUSION OF ADENOSINE TO HUMAN PATIENTS) | ⤷ Try a Trial |
| Denmark | 253187 | ⤷ Try a Trial | |
| Germany | 19975044 | ⤷ Try a Trial | |
| European Patent Office | 0354638 | ⤷ Try a Trial | |
| Japan | 2914454 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
